In a phase II clinical trial for non-Hodgkin’s Lymphoma and Hodgkin’s Lymphoma, IL12 administration increased circulating CD8+ T-cell presence but had no effect on CD4+ T-cell presence38. The gene discussed is CD8A; the disease is Hodgkins lymphoma.